Evidence map›Paper›PMID 36177900›Full record

ArticleOncology reports2022

MYCL promotes the progression of triple‑negative breast cancer by activating the JAK/STAT3 pathway.

Hongnan Jiang, Xiaojun Li, Wei Wang, Yaofeng Hu, Dongliang Ren

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hongnan JiangDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xiaojun LiDepartment of Radiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Wei WangDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Yaofeng HuDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Dongliang RenDepartment of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Shanxi Medical University · CNSecond Hospital of Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to investigate the underlying regulatory mechanism of MYCL proto‑oncogene (MYCL) in triple‑negative breast cancer (TNBC) progression.

Indexed as

Proto-Oncogene Proteins c-mycTriple Negative Breast NeoplasmsApoptosisCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansSTAT3 Transcription FactorMYCL protein, humanProto-Oncogene Proteins c-mycSTAT3 protein, humanSTAT3 Transcription FactorJAK/STAT3 pathwaymigrationMYCL proto‑oncogeneproliferationtriple‑negative breast cancer

Identifiers

PMID36177900
PMCPMC9551653
OpenAlexW4298003121

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.